Case Study and Clinical Highlight: Diagnosis of Pulmonary Involvement in Systemic Sclerosis

Case Study and Clinical Highlight: Diagnosis of Pulmonary Involvement in Systemic Sclerosis

Engage in this case study to test your diagnostic ability to differentiate pulmonary hypertension in the setting of systemic sclerosis.

Latest News

Risk Factors for Scleroderma Renal Crisis in Systemic Sclerosis

Risk Factors for Scleroderma Renal Crisis in Systemic Sclerosis

Researchers identify risk factors for scleroderma renal crisis in patients with systemic sclerosis.

Strong Reproducibility for 6-Minute Walk Test in Systemic Sclerosis

Strong Reproducibility for 6-Minute Walk Test in Systemic Sclerosis

Investigators assessed the reproducibility and the utility of the 6-minute walk test in systemic sclerosis.

Little Data Available for Small Intestinal Bacterial Overgrowth Treatment in Systemic Sclerosis

Little Data Available for Small Intestinal Bacterial Overgrowth Treatment in Systemic Sclerosis

For some patients with systemic sclerosis, antibiotics can eradicate small intestinal bacterial overgrowth.

SPAR Model May Predict Mild Interstitial Lung Disease in Systemic Sclerosis

SPAR Model May Predict Mild Interstitial Lung Disease in Systemic Sclerosis

The SPAR prediction model might be helpful for the risk stratification of mild ILD in patients with SSc in clinical practice.

PAH in Systemic Sclerosis Increases Risk for Early Mortality

PAH in Systemic Sclerosis Increases Risk for Early Mortality

The majority of deaths in patients with systemic sclerosis-associated pulmonary arterial hypertension occurred within 4 years of diagnosis.

Sildenafil, Bosentan Combination vs Sildenafil Monotherapy in SSc-Associated PAH

Sildenafil, Bosentan Combination vs Sildenafil Monotherapy in SSc-Associated PAH

There was no significant difference in efficacy between sildenafil and bosentan initial combination therapy and sildenafil monotherapy in patients with systemic sclerosis-related pulmonary arterial hypertension.

Smoking Not Associated With Systemic Sclerosis-Specific Cutaneous, Pulmonary Manifestations

Smoking Not Associated With Systemic Sclerosis-Specific Cutaneous, Pulmonary Manifestations

Smoking status in patients with systemic sclerosis was not significantly associated with systemic sclerosis-specific cutaneous or pulmonary changes.

PAH-Associated Connective Tissue Diseases: A Case for Separating SSc, SLE

PAH-Associated Connective Tissue Diseases: A Case for Separating SSc, SLE

Recent evidence suggests that systemic sclerosis and SLE in pulmonary arterial hypertension should be considered separate diseases.

LPA1 Receptor Antagonist SAR100842 Safe, Well Tolerated in Systemic Sclerosis

LPA1 Receptor Antagonist SAR100842 Safe, Well Tolerated in Systemic Sclerosis

The investigational drug SAR100842 was safe, moderately effective, and well tolerated in patients with early diffuse cutaneous systemic sclerosis.

Expert Insight: Detecting Pulmonary Arterial Hypertension in Patients With Systemic Sclerosis

Expert Insight: Detecting Pulmonary Arterial Hypertension in Patients With Systemic Sclerosis

Although pulmonary arterial hypertension occurs in a minority of patients with systemic sclerosis, clinicians must be attentive to it, as it can emerge at any point over the course of the disease.

Sign Up for Free e-newsletters